Table 3.
Composition of the selected modified coconut oils (MCO1–MCO6) produced by local G. candidum through DIMOSFER process along with their antibacterial activities.
| Sample | SSF condition | Product composition (%) | ABA (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Moisture content (%) | Oil content (%) | Incubation time (day) | MCTG | MCDG | MCMG | MCFA | E. coli | S. aureus | |
| MCO1 | 32 | 50 | 30 | 80 | 15 | 1 | 14 | 15 | 20 |
| MCO2 | 42 | 10 | 10 | 54 | 20.52 | 2.64 | 22.4 | 71 | 75 |
| MCO3 | 30 | 0 | 16 | 54.5 | 9.8 | 4.65 | 31.14 | 60 | 63 |
| MCO4 | 30 | 25 | 10 | 38 | 20.32 | 0.5 | 40.5 | 75 | 80 |
| MCO5 | 50 | 25 | 16 | 44.5 | 7.8 | 1 | 47 | 78 | 85 |
| MCO6 (opt) | 30 | 10 | 9 | 24 | 16.55 | 6.45 | 53 | 80 | 90 |
| Coconut oil | 99 | 1 | 0 | 0 | 3.1 | 4.8 | |||
| Without oil | — | — | — | — | 0* | 0* | |||
MCO1–MCO6: modified coconut oils obtained from DIMOSFER by local G. candidum strain.
Opt: optimum condition obtained from optimization of coconut oil hydrolysis through DIMOSFER process.
Composition: MCTG: medium chain triglyceride; MCDG: medium chain diglyceride; MCMG: medium chain monoglyceride; and MCFA: medium chain fatty acid.
ABA: antibacterial activity.
Pathogenic bacteria: Escherichia coli (ATCC 10536) and Staphylococcus aureus (ATCC 25923).
∗ Escherichia coli (1.44 × 108 CFU/mL) and Staphylococcus aureus (1.30 × 108 CFU/mL).